Search for Clinical Trial Results

Sponsored By

Merkel Cell Carcinoma - 25 Studies Found

Status Study
Recruiting Study Name: MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2015-07-28
Interventions: Drug: MLN0128 Investigational mTOR kinase inhibitor
Recruiting Study Name: F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2014-01-31
Interventions:
  • Drug: Arm A: F16IL2 in combination with paclitaxel

Active, not recruiting Study Name: A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2014-01-10
Interventions: Biological: GLA-SE Glucopyranosyl Lipid A in Stable Emulsion
Recruiting Study Name: Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With 3 mg/kg BW Ipilimumab (Yervoy®) Versus Observation
Condition: Merkel Cell Carcinoma
Date: 2014-06-20
Interventions: Drug: Ipilimumab adjuvant treatment of completely resected Merkel cell carcinoma
Available Study Name: Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)
Condition: Metastatic Merkel Cell Carcinoma
Date: 2017-03-20
Interventions: Drug: Avelumab Avelumab should be administered intravenously as per the recommended dose. Administration
Withdrawn Study Name: Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
Condition: Merkel Cell Carcinoma
Date: 2013-07-28
Interventions: Drug: Ipilimumab Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is comm
Terminated Study Name: Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma
Condition:
  • Recurrent Merkel Cell Carcinoma
  • Stage IV
    Date: 2012-12-27
    Interventions:
    • Biological: Aldesleukin Given

Completed Study Name: IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer
Condition: Merkel Cell Carcinoma
Date: 2011-09-23
Interventions:
  • Biological: interleukin-12 gene

Completed Study Name: A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma
Condition: Metastatic Melanoma and Merkel Cell Carcinoma
Date: 2012-07-12
Interventions:
  • Drug: Pasireotide sub-cutaneous formulation

Active, not recruiting Study Name: Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Condition:
  • Merkel Cell Carcinoma
  • Skin Cancer

Date: 2013-12-19
Interventions: Drug: Cabozantinib Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
Next >>>